Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Profits May Not Reveal Underlying Issues

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) robust recent earnings didn't do much to move the stock. However the statutory profit number doesn't tell the whole story, and we h

Simply Wall StApr 29 19:16 ET

Nootech Biotech (688076.SH): Net profit of 66.326,800 yuan in the first quarter increased 215.65% year-on-year

Gelonghui, April 22丨Nuotai Biotech (688076.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 356 million yuan, up 71.02% year on year; net profit attributable to shareholders of listed companies was 66.368 million yuan, up 215.65% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 65.3985 million yuan, up 179.69% year on year; basic earnings per share were 0.31 yuan.

Gelonghui FinanceApr 22 04:18 ET

Is There An Opportunity With Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) 22% Undervaluation?

Key Insights The projected fair value for Jiangsu Sinopep-Allsino Biopharmaceutical is CN¥65.49 based on 2 Stage Free Cash Flow to Equity Jiangsu Sinopep-Allsino Biopharmaceutical's CN¥51.01 share p

Simply Wall StApr 17 03:46 ET

Nootech Biotech (688076.SH) posted an advance increase. Net profit for the first quarter is expected to be 55 million yuan to 70 million yuan, a year-on-year increase of 161.74% to 233.13%

Nootech Biotech (688076.SH) issued an announcement. According to preliminary estimates by the finance department, the company's first quarter of 2024...

Zhitong FinanceApr 3 04:01 ET

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) has had a great run on the share market with its stock up by a significant 38% over the last three months. Given that stock prices are usually

Simply Wall StMar 27 01:29 ET

Starlink Management, a shareholder of Nordtech Biotech (688076.SH), reduced its holdings by a total of 74,100 shares, and the reduction period expired

Zhitong Finance App News, Nuotai Biotech (688076.SH) issued an announcement. The company recently received a “Notice of Stock Reduction Results” from the shareholder Jiande Xinglian Enterprise Management Co., Ltd. (hereinafter referred to as “Starlink Management”). The holdings reduction plan has expired. During the holdings reduction plan period, Starlink Management has reduced its holdings of the company's shares by a total of 74,100 shares, accounting for 0.03% of the total share capital.

Zhitong FinanceMar 1 05:54 ET